公开(公告)号：US20210379022A1

公开(公告)日：2021-12-09

申请号：US17285464

申请日：2019-09-03

申请人： KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES

发明人： Jae Sung KIM ,  Ah Young KIM ,  Sang Gu HWANG ,  Jie Young SONG ,  Yi Na YOON

IPC分类号： A61K31/4184 ,  A61P35/00 ,  A23L33/10

摘要： The present invention relates to a pharmaceutical composition for preventing or treating cancer, a radiosensitizer composition for treating cancer, and a health functional food for preventing or improving cancer, which comprise N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl) benzamide, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition comprising N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl) benzamide or a derivative thereof as an active ingredient according to the present invention arrests the mitosis of cancer cells to prevent proliferation and at the same time, to exhibit low toxicity in normal cell lines and induce apoptosis only in cancer cell lines, so it can be used as an effective anticancer agent. In addition, the N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl) benzamide of the present invention can increase the sensitivity of the treated cancer cells to radiation, so it can be used as a radiosensitizer composition for cancer treatment.

公开(公告)号：US20160298119A1

公开(公告)日：2016-10-13

申请号：US15025872

申请日：2014-09-04

申请人： KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES

发明人： Sang Gu HWANG ,  Hong Shik YUN

IPC分类号： C12N15/113 ,  A61K45/06 ,  A61K31/475 ,  A61K39/395 ,  A61K31/704 ,  C07K16/22 ,  A61K31/7088

CPC分类号： C12N15/1136 ,  A61K31/475 ,  A61K31/704 ,  A61K31/7088 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/22 ,  C07K2317/76 ,  C12N2310/14 ,  C12N2320/31

摘要： The present invention relates to a pharmaceutical composition for treating a radiation- or drug-resistant cancer, containing an agent capable of inhibiting the expression of hepatoma-derived growth factor (HDGF)-related protein-3 (HRP-3), a method of treating a radiation- or drug-resistant cancer by administering the pharmaceutical composition, and the use of an HRP-3 inhibitor for preparing an agent for treating a radiation- or drug-resistant cancer. The use of the pharmaceutical composition of the present invention enables to treat a resistant cancer in combination with a conventional anticancer chemotherapy or radiotherapy. Accordingly, the pharmaceutical composition of the present invention can reduce both the costs for developing anticancer agents against resistant cancers and the costs for treating cancers in patients, thus being useful for the economic and effective treatment of resistant cancers.

摘要翻译： 本发明涉及一种含有能够抑制肝癌来源的生长因子（HDGF）相关蛋白-3（HRP-3）表达的药物的放射线或耐药性癌症的治疗药物组合物， 通过施用药物组合物来治疗放射性或耐药性癌症，以及使用HRP-3抑制剂来制备用于治疗放射线或耐药性癌症的药剂。 使用本发明的药物组合物能够结合常规的抗癌化学疗法或放射治疗来治疗耐药性癌症。 因此，本发明的药物组合物可以降低开发抗癌剂对耐药性癌症的成本和治疗癌症患者的成本，因此可有效治疗耐药性癌症。